Oxaliplatin Kabi

Oxaliplatin, the active ingredient in Oxaliplatin Kabi, is a chemotherapy agent presented as a sterile solution for intravenous use. It is employed in the treatment of colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Kabi is used in colorectal cancer treatment protocols and related gastrointestinal oncology pathways.

- Colorectal cancer: enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: contributes to disease control in combination chemotherapy. - Pancreatic cancer: used off‑label in some regimens to improve response rates. - Esophageal cancer: added to multi‑drug protocols for potential benefit. - Metastatic disease: part of combination therapy to manage spread of gastrointestinal tumors. - Adjuvant therapy: employed after surgical resection to reduce recurrence risk.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during treatment.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhea: loose stools that may require supportive care. - Fatigue: generalized tiredness during therapy. - Myelosuppression: reduced blood cell counts. - Electrolyte disturbances: changes in potassium or magnesium levels.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or infusion‑related hypersensitivity. - Acute neurotoxicity: sudden onset of muscle cramps or difficulty breathing. - Cardiac arrhythmias: irregular heart rhythms observed during infusion. - Renal impairment: decreased kidney function requiring dose adjustment. - Hemolytic anemia: destruction of red blood cells. - Thrombotic events: blood clot formation in veins or arteries.

When using Oxaliplatin Kabi, clinicians should observe several safety measures to minimize risks.

- Renal function assessment: evaluate baseline creatinine and glomerular filtration rate. - Neuropathy monitoring: conduct regular neurological examinations. - Hematologic surveillance: perform frequent complete blood counts. - Electrolyte management: check and correct potassium and magnesium levels. - Infusion rate control: administer over the recommended time to reduce toxicity. - Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin Kabi can interact with other medicines, influencing its safety and effectiveness.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use may worsen kidney injury. - Myelosuppressive drugs: combined effect can cause severe bone‑marrow suppression. - Antioxidants (high dose): may reduce platinum‑drug efficacy.

Moderate Interactions (Monitor Closely): - Anti‑emetics: may require dose adjustment for optimal control of nausea. - Calcium channel blockers: potential for altered drug clearance. - NSAIDs: increased risk of renal dysfunction when used together.